{"id":1027,"date":"2024-05-22T11:39:22","date_gmt":"2024-05-22T11:39:22","guid":{"rendered":"https:\/\/retirednurseblog.com\/index.php\/2024\/05\/22\/many-people-using-glp-1s-for-weight-loss-stop-treatment-too-soon-research-shows-and-results-are-not-one-size-fits-all\/"},"modified":"2024-05-22T11:39:22","modified_gmt":"2024-05-22T11:39:22","slug":"many-people-using-glp-1s-for-weight-loss-stop-treatment-too-soon-research-shows-and-results-are-not-one-size-fits-all","status":"publish","type":"post","link":"https:\/\/retirednurseblog.com\/index.php\/2024\/05\/22\/many-people-using-glp-1s-for-weight-loss-stop-treatment-too-soon-research-shows-and-results-are-not-one-size-fits-all\/","title":{"rendered":"Many people using GLP-1s for weight loss stop treatment too soon, research shows, and results are not one-size-fits-all"},"content":{"rendered":"
\n

Demand for Wegovy and other GLP-1 drugs used to treat obesity and diabetes has skyrocketed, but a new report suggests that many people may not be sticking with their weight-loss treatment long enough. <\/p>\n

An analysis of health insurance claims released Tuesday found that most people using GLP-1 medications \u2013 about 58% \u2013 were on their treatment plan for less than 12 weeks, falling short of a key benchmark in the weight-loss treatment timeline. Professional organizations have set this as a guideline for when to reassess whether a treatment is providing clinically meaningful weight loss. <\/p>\n

Users start with a low dose of these medications and gradually increase it over time <\/strong>until they reach a targeted dose. But the analysis shows that nearly a third of people \u2013 more than 30% \u2013 dropped out after the first four weeks of treatment, before reaching the targeted dose. <\/p>\n

The findings are based on pharmacy and medical claims data for about 170,000 people with insurance coverage under Blue Cross Blue Shield plans who were prescribed GLP-1 medications that were approved to treat weight management between 2014 and 2023. <\/p>\n

\u201cThese are long-term medications to treat a chronic disease,\u201d said Dr. Disha Narang, an endocrinologist and director of obesity medicine at Endeavor Health in Chicago, who <\/strong>was not involved in the new research. <\/strong>\u201cThis is absolutely a marathon, not a sprint. And when we do treat this as a sprint, I think patients are likely to get off of medication much faster.\u201d <\/p>\n

Experts say that impatience with results is one of many reasons patients might stop treatment. Only about two-thirds of adults who have used injectable weight-loss drugs say they feel that they were effective, according to a new KFF poll. And people who stopped using the medications were significantly less optimistic about their benefits: Only about half of those who had used injectable weight-loss drugs in the past said they were effective, compared with nearly three-quarters of those who were actively using the treatments. <\/p>\n

Side effects \u2013 such as nausea, diarrhea, vomiting and constipation that are common early on \u2013 may also drive people away. Data from the longest clinical trial of Wegovy showed that 17% of people using the drug decided to stop participating in the trial because of side effects. <\/p>\n

But experts say that many deterrents can be managed with appropriate counseling from a provider. <\/p>\n

\u201cIf you don\u2019t have frequent touchpoints, frequent interactions, then it\u2019s really it\u2019s hard to manage side effects. It\u2019s hard to manage expectations. It\u2019s hard to see if there\u2019s improvement in some of these other metabolic comorbidities,\u201d said Dr. Jody Dushay, an endocrinologist at Beth Israel Deaconess Medical Center and assistant professor of medicine at Harvard Medical School who <\/strong>was not involved in the new research. <\/strong> <\/p>\n

Each person will respond to treatment differently and assess the balance of costs and benefits to their heath differently. <\/p>\n

\u201cThere\u2019s not a line in the sand for every single person. Physicians and patients have to just look at all the data and make a decision about treatment together,\u201d she said. <\/p>\n

Findings from the Blue Cross Blue Shield data emphasize the important role that providers can play in helping patients stick with their treatment with GLP-1s. <\/p>\n

People who met with their providers less frequently \u2013 and those living in underserved regions with broader health inequities \u2013 were more likely to discontinue GLP-1 treatment sooner. Each additional follow-up visit increased a patient\u2019s chances of staying on the treatment by 60%, said Dr. Razia Hashmi, vice president of clinical affairs for the Blue Cross Blue Shield Association. <\/p>\n

And although most prescriptions came from primary care physicians, those who were prescribed GLP-1s by endocrinologists or others with expertise in weight management were more likely to reach at least 12 weeks of continuous treatment. <\/p>\n

\u201cWraparound support services really make a difference \u2013 whether a person has lifestyle support management, nutrition, diet and side effect management,\u201d Hashmi said, and \u201chealth equity matters. Social drivers of health \u2013 transportation, access to food, socioeconomic status \u2013 all of that also makes a difference.\u201d <\/p>\n

Cost can often be a prohibitive factor for these medications \u2013 a month\u2019s supply of GLP-1 medications can often cost about $1,000 \u2013 but the analysis included only people who had insurance plans that covered weight-loss medication prescriptions. Insurance plan copays may have affected cost considerations, but the individuals in this analysis were not paying out-of-pocket for their treatment. <\/p>\n

But using GLP-1 treatments are still an investment in many ways. <\/p>\n

\u201cWhether it\u2019s an employer trying to make a decision or an individual patient trying to make a decision, it\u2019s really important to understand the success factors,\u201d Hashmi said. \u201cWe want the investment to pay off.\u201d <\/p>\n

Another new report supports the claim that the benefits of GLP-1s are extended with long-term, consistent treatment. <\/p>\n

One of the first reports offering real-world data on GLP-1 efficacy found that people using the medicines had lost an average of about 1.4% of their starting body weight after three months, which steadily increased to an average of about 3% weight loss after a full year on the treatment. The analysis from Dandelion Health, a health care analytics firm, is based on the electronic health records of nearly 17,000 people who were prescribed a GLP-1 from 2019 through 2023. <\/p>\n

Compared with a group of people with a similar set of clinical characteristics \u2013 matched closely on demographic factors such as age and ethnicity, treatment indicators such as average body mass index and diabetes prevalence, history of treatments such as bariatric surgery and prevalence of related comorbidities \u2013 the analysis found that those on GLP-1s lost about twice as much weight. <\/p>\n

These injected medications, called GLP-1 agonists, are in high demand because they have proved to be so effective for weight loss.\u00a0In clinical trials, some of the stronger medications like Wegovy and Zepbound have been found to help people lose\u00a0at least 10% of their starting weight.\u00a0But the <\/strong>new report suggests that the real-world efficacy is not as promising as clinical trial data would suggest. <\/p>\n

\n
    <\/ul>\n<\/div>\n

    And experts warn that the GLP-1 treatment process can be different for everyone. <\/p>\n

    \u201cThere are some people who are under-responders, there are some people who are over-responders, and there\u2019s some that respond as expected to the medication,\u201d Narang said. \u201cStudies are still happening to understand why.\u201d <\/p>\n

    The data from Dandelion Health showed that the 10% of people with the best response to GLP-1s had results that mirrored what clinical trials found, but the 10% with the least success with the treatments had no weight change, or even an increase in weight, over time. <\/p>\n

    Still, GLP-1 medications may have benefits far beyond weight loss \u2013 for heart and liver health, for example \u2013 which may extend even to people who don\u2019t lose as many pounds as they might have expected, experts say. <\/p>\n

    \u201cIt\u2019s really important to not use the scale as the only outcome of whether you should stay on this medication. People might be making slow but steady progress, which could warrant ongoing treatment,\u201d Dushay said. \u201cThere may be some direct benefits of the medication in the absence of significant weight loss, which is also why you should be talking to your doctor at length about why you\u2019re using this medication.\u201d <\/p>\n<\/p>\n

    This post appeared first on cnn.com<\/div>\n<\/div>\n\n","protected":false},"excerpt":{"rendered":"

    Demand for Wegovy and other GLP-1 drugs used to treat obesity and diabetes has skyrocketed, but a new report suggests that many people may not be sticking with their weight-loss treatment long enough. An analysis of health insurance claims released Tuesday found that most people using GLP-1 medications \u2013 about 58% \u2013 were on their …<\/p>\n","protected":false},"author":1,"featured_media":1028,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"loftocean_post_primary_category":0,"loftocean_post_format_gallery":"","loftocean_post_format_gallery_ids":"","loftocean_post_format_gallery_urls":"","loftocean_post_format_video_id":0,"loftocean_post_format_video_url":"","loftocean_post_format_video_type":"","loftocean_post_format_video":"","loftocean_post_format_audio_type":"","loftocean_post_format_audio_url":"","loftocean_post_format_audio_id":0,"loftocean_post_format_audio":"","loftocean-featured-post":"","loftocean-like-count":0,"loftocean-view-count":596,"tinysalt_single_post_intro_label":"","tinysalt_single_post_intro_description":"","tinysalt_hide_post_featured_image":"","tinysalt_post_featured_media_position":"","tinysalt_single_site_header_source":"","tinysalt_single_custom_site_header":"0","tinysalt_single_custom_sticky_site_header":"0","tinysalt_single_custom_sticky_site_header_style":"sticky-scroll-up","tinysalt_single_site_footer_source":"","tinysalt_single_custom_site_footer":"0","footnotes":""},"categories":[35],"tags":[],"class_list":["post-1027","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health-news"],"_links":{"self":[{"href":"https:\/\/retirednurseblog.com\/index.php\/wp-json\/wp\/v2\/posts\/1027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/retirednurseblog.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/retirednurseblog.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/retirednurseblog.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/retirednurseblog.com\/index.php\/wp-json\/wp\/v2\/comments?post=1027"}],"version-history":[{"count":0,"href":"https:\/\/retirednurseblog.com\/index.php\/wp-json\/wp\/v2\/posts\/1027\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/retirednurseblog.com\/index.php\/wp-json\/wp\/v2\/media\/1028"}],"wp:attachment":[{"href":"https:\/\/retirednurseblog.com\/index.php\/wp-json\/wp\/v2\/media?parent=1027"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/retirednurseblog.com\/index.php\/wp-json\/wp\/v2\/categories?post=1027"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/retirednurseblog.com\/index.php\/wp-json\/wp\/v2\/tags?post=1027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}